pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-2864Research ArticleЛЕКЦИИLECTIONSКомбинированный препарат “симбикорт” и его место в терапии бронхиальной астмыThe combined drug “Simbikort” and its role in bronchial asthma therapyКняжескаяН. П.KnyazheskayaN. P.
Кафедра пульмонологии
ФУВ РГМУRussian Federation20013012200104118122Copyright © Княжеская Н.П., 20012001Княжеская Н.П.Knyazheskaya N.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2864
.
.
ReferencesБронхиальная астма. Глобальная стратегия: совместный доклад Национального института Сердце, Легкие, Кровь и Всемирной организации здравоохранения. Русская версия под общ. ред. акад. А.Г.Чучалина. Пульмонология, 1996; прил.:1 — 165.Бронхиальная астма. Глобальная стратегия: совместный доклад Национального института Сердце, Легкие, Кровь и Всемирной организации здравоохранения. Русская версия под общ. ред. акад. А.Г.Чучалина. Пульмонология, 1996; прил.:1 — 165.Бронхиальная астма. Руководство для врачей России (формулярная система). Там же, 1999; прил.: 1—40.Бронхиальная астма. Руководство для врачей России (формулярная система). Там же, 1999; прил.: 1—40.Калманова Е.Н., Айсанов З.Р. Форадил и его место в терапии бронхиальной астмы. Там же, 2001; 1: 65—72.Калманова Е.Н., Айсанов З.Р. Форадил и его место в терапии бронхиальной астмы. Там же, 2001; 1: 65—72.Формулярная система: лечение бронхиальной астмы. Астма.ru 0. 2001; 6—9.Формулярная система: лечение бронхиальной астмы. Астма.ru 0. 2001; 6—9.Чучалин А.Г. Бронхиальная астма. М.; 1997, т.1—2.Чучалин А.Г. Бронхиальная астма. М.; 1997, т.1—2.Agertoft L., Pedersen S. Effect of long-term treatment with inhaled biidesonide on adult height in children with asthma. N. Engl. J. Med. 2000; 343: 1064—1069.Agertoft L., Pedersen S. Effect of long-term treatment with inhaled biidesonide on adult height in children with asthma. N. Engl. J. Med. 2000; 343: 1064—1069.Andersson F. et al. The costs and effects of adding formoterol to budesonide — results of the FACET Study. Am. J. Respir. Crit. Care Med. 1999; 159 (3, Pt.2): A762.Andersson F. et al. The costs and effects of adding formoterol to budesonide — results of the FACET Study. Am. J. Respir. Crit. Care Med. 1999; 159 (3, Pt.2): A762.Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of highly potent and selective agonist bronchodilatator. Life Sei. 1993; 52: 2145—2160.Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of highly potent and selective agonist bronchodilatator. Life Sei. 1993; 52: 2145—2160.Ankerst J., Persson G., Weibull E. A high dose of budesonide/formoterol in a single inhaler was well tolerated by asthmatic patients. Eur. Respir. J. 2000; 16 (suppl.31): 33s+poster.Ankerst J., Persson G., Weibull E. A high dose of budesonide/formoterol in a single inhaler was well tolerated by asthmatic patients. Eur. Respir. J. 2000; 16 (suppl.31): 33s+poster.Barney P.G.J. Current questions in the epidemiology of asthma. In: Holgate S.Т., et al. Asthma: Physiology. Immunology, and Treatment. London: Academic Press; 1993. 3—25.Barney P.G.J. Current questions in the epidemiology of asthma. In: Holgate S.Т., et al. Asthma: Physiology. Immunology, and Treatment. London: Academic Press; 1993. 3—25.Crisholm S. et al. Once-daily budesonide in mild asthma. Respir. Med. 1998; 92: 421—425.Crisholm S. et al. Once-daily budesonide in mild asthma. Respir. Med. 1998; 92: 421—425.Juniper E.F., Svensson K., Byrne P.M. et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur. Respir. J. 1999; 14: 1038—1043.Juniper E.F., Svensson K., Byrne P.M. et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur. Respir. J. 1999; 14: 1038—1043.Kips J.C., O’Connor B.J., Inman M.D. et al. A long-termed study of the antiinflammatory effect of low-dosed budesonide plus formoterol versus high-dosed budesonide in asthma. Am. Respir. Crit. Care Med. 2000; 161: 996—1001.Kips J.C., O’Connor B.J., Inman M.D. et al. A long-termed study of the antiinflammatory effect of low-dosed budesonide plus formoterol versus high-dosed budesonide in asthma. Am. Respir. Crit. Care Med. 2000; 161: 996—1001.McFadden E.R., Casale T.B., Edwards T.B. et al. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. J. Allergy Clin. Immunol. 1999; 104: 46—52.McFadden E.R., Casale T.B., Edwards T.B. et al. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. J. Allergy Clin. Immunol. 1999; 104: 46—52.Miller-Larsson A. et. al. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am. J. Respir. Crit. Care Med. 2000; 162: 1455—1461.Miller-Larsson A. et. al. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am. J. Respir. Crit. Care Med. 2000; 162: 1455—1461.Miller-Larsson A., Mattsson H., Hjertberg E., et al. Reversible fatty acid conjugation of budesonide: novel mechanism foe prolonged retention of topically applied steroid in airway tissue. Drug Metab. Dispos. 1998; 26: 623—630.Miller-Larsson A., Mattsson H., Hjertberg E., et al. Reversible fatty acid conjugation of budesonide: novel mechanism foe prolonged retention of topically applied steroid in airway tissue. Drug Metab. Dispos. 1998; 26: 623—630.Molimard M. et al. Long- and short-adrenoreceptor agonists: interactions in human contracted bronchi. Eur. Respir. J. 1998; 11: 583—588.Molimard M. et al. Long- and short-adrenoreceptor agonists: interactions in human contracted bronchi. Eur. Respir. J. 1998; 11: 583—588.O’Connor B.J., Alkinan S.L., Barnes P.J. Tolerance to the non-bronchodilatator effects of inhaled ß2-agonists in asthma. N. Engl. J. Med. 1992; 327: 1204—1208.O’Connor B.J., Alkinan S.L., Barnes P.J. Tolerance to the non-bronchodilatator effects of inhaled ß2-agonists in asthma. N. Engl. J. Med. 1992; 327: 1204—1208.Palmquist M. et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 1999; 160: 244—249.Palmquist M. et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 1999; 160: 244—249.Palmquist M. et al. Inhaled dry powder formoterol and salmererol in asthmatic patients: onset of action, duration of effect and potency. Eur. Respir. J. 1997; 10: 2484—2489.Palmquist M. et al. Inhaled dry powder formoterol and salmererol in asthmatic patients: onset of action, duration of effect and potency. Eur. Respir. J. 1997; 10: 2484—2489.Pauwels R.A. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 1997; 337: 1405—1411.Pauwels R.A. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 1997; 337: 1405—1411.Pedersen S., O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroides in asthma. Allergy 1997; 52 (suppl.39): 1—34.Pedersen S., O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroides in asthma. Allergy 1997; 52 (suppl.39): 1—34.Politiek M.J., Boorsma M., Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur. Respir. J. 1999; 13: 988—992.Politiek M.J., Boorsma M., Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur. Respir. J. 1999; 13: 988—992.The British Guidelines on Asthma Management. Thorax, 1997; 52 (suppl.l): 1—20.The British Guidelines on Asthma Management. Thorax, 1997; 52 (suppl.l): 1—20.Woolcock A. et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 1996; 153: 1481—1488.Woolcock A. et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 1996; 153: 1481—1488.
The authors declare that there are no conflicts of interest present.